
(IN BRIEF) Alexion, in collaboration with AstraZeneca Rare Disease, has finalized an agreement to acquire a collection of preclinical rare disease gene therapy programs and related technologies from Pfizer Inc. This strategic move combines the expertise of Alexion and AstraZeneca … Read the full press release